NCT03702725 Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03697512 MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03689894 Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Status TERMINATED Phase PHASE1/PHASE2
NCT03684694 Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT03679624 Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia Status TERMINATED Phase PHASE2
NCT03642236 Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML Status UNKNOWN Phase PHASE2/PHASE3
NCT03617484 Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma Status WITHDRAWN Phase PHASE2
NCT03581942 Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) Status COMPLETED Phase PHASE1/PHASE2
NCT03535350 Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03525925 Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT03514017 Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia Status TERMINATED Phase PHASE2
NCT03513562 Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03506373 Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Status TERMINATED Phase PHASE2
NCT03479268 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03478514 Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03476655 Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India Status COMPLETED Phase N/A
NCT03474679 A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Status COMPLETED Phase PHASE3
NCT03462719 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03447808 Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1